Reply - 03/03/22

| Disclosure of potential conflict of interest: S. E. Wenzel declares unrelated potential conflicts of interest in connection with consulting with Sanofi (dupilumab), AstraZeneca (tezepelumab), GSK (mepolizumab), and Knopp (dexpramipexole), as well as with multicenter research grants from AstraZeneca (tezepelumab and benralizumab), GSK (anti–IL-33), and Knopp Bioscience (dexpramipexole); in addition, she has received unrestricted research support for the Severe Asthma Research Program (unrelated to this study) from TEVA and Boehringer Ingelheim and institutional research support from Pieris. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 149 - N° 3
P. 1132-1133 - mars 2022 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
